It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December that it closed Fund XIV with $450m to invest in biopharmaceutical start-ups, matching the $450m total of Fund XIII, which closed in March 2022.
Finance Watch: Atlas Raises Another $450m Fund To Back Start-Ups
Fund XIV Matches Fund XIII From 2022
Private Company Edition: Atlas Venture closed its $450m Fund XIV after some notable exits. Also, Nuvig’s $161m series B round more than triples its $47m series A from 2022, while Maze’s $115m series D fell below its prior $190m round and Antag raised an €80m ($84.7m) series A.
More from Finance Watch
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.